{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:21:47Z","timestamp":1790734907522,"version":"4.1.0"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12265-025-10603-4","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T11:45:01Z","timestamp":1741866301000},"page":"703-722","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9654-769X","authenticated-orcid":false,"given":"Abbas","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azin","family":"Karimian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasra","family":"Shokri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashkan","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nazanin","family":"Hazhir-Karzar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayeheh","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azar","family":"Radfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadreza","family":"Pakyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Tehrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"10603_CR1","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","volume":"130","author":"TM Powell-Wiley","year":"2022","unstructured":"Powell-Wiley TM, Baumer Y, Baah FO, et al. Social determinants of cardiovascular disease. Circ Res. 2022;130:782\u201399.","journal-title":"Circ Res"},{"key":"10603_CR2","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation. 2023;148:1606\u201335.","journal-title":"Circulation"},{"key":"10603_CR3","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart association. Circulation. 2023;148:1636\u201364.","journal-title":"Circulation"},{"key":"10603_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1161\/CIRCULATIONAHA.123.067373","volume":"149","author":"VJ Dzau","year":"2024","unstructured":"Dzau VJ, Hodgkinson CP. RNA therapeutics for the cardiovascular system. Circulation. 2024;149:707\u201316.","journal-title":"Circulation"},{"key":"10603_CR5","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/HCO.0000000000000850","volume":"36","author":"C Boada","year":"2021","unstructured":"Boada C, Sukhovershin R, Pettigrew R, Cooke JP. RNA therapeutics for cardiovascular disease. Curr Opin Cardiol. 2021;36:256\u201363.","journal-title":"Curr Opin Cardiol"},{"key":"10603_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1089\/oli.2010.0252","volume":"20","author":"MS Baek","year":"2010","unstructured":"Baek MS, Yu RZ, Gaus H, Grundy JS, Geary RS. In vitro metabolic stabilities and metabolism of 2\u2019-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates. Oligonucleotides. 2010;20:309\u201316.","journal-title":"Oligonucleotides"},{"issue":"6","key":"10603_CR7","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.3390\/cells9061473","volume":"9","author":"M Zaiou","year":"2020","unstructured":"Zaiou M. The emerging role and promise of circular RNAs in obesity and related metabolic disorders. Cells. 2020;9(6):1473.","journal-title":"Cells"},{"key":"10603_CR8","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","volume":"40","author":"VJ Alexander","year":"2019","unstructured":"Alexander VJ, Xia S, Hurh E, et al. N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. Eur Heart J. 2019;40:2785\u201396.","journal-title":"Eur Heart J"},{"key":"10603_CR9","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","volume":"27","author":"ST Crooke","year":"2018","unstructured":"Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metab. 2018;27:714\u201339.","journal-title":"Cell Metab"},{"key":"10603_CR10","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif JC, Karwatowska-Prokopczuk E, Amour ES, et al. Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart J. 2022;43:1401\u201312.","journal-title":"Eur Heart J"},{"key":"10603_CR11","doi-asserted-by":"publisher","first-page":"115978","DOI":"10.1016\/j.taap.2022.115978","volume":"443","author":"D Lehoux","year":"2022","unstructured":"Lehoux D, Far AR, Kallend D, Wijngaard PLJ, Zerler B. Evaluation of the distribution and excretion of [(14)C]-inclisiran following single subcutaneous administration in cynomolgus monkeys. Toxicol Appl Pharmacol. 2022;443:115978.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"Suppl 2","key":"10603_CR12","first-page":"34","volume":"31","author":"M Blasco","year":"2019","unstructured":"Blasco M, Ascaso JF. Control of the overall lipid profile. Clin Investig Arterioscler. 2019;31(Suppl 2):34\u201341.","journal-title":"Clin Investig Arterioscler"},{"key":"10603_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12944-022-01649-3","volume":"21","author":"DJ Blom","year":"2022","unstructured":"Blom DJ, Marais AD, Moodley R, van der Merwe N, van Tonder A, Raal FJ. RNA-based therapy in the management of lipid disorders: a review. Lipids Health Dis. 2022;21:41.","journal-title":"Lipids Health Dis"},{"key":"10603_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342.","journal-title":"N Engl J Med"},{"key":"10603_CR15","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.jacbts.2023.04.005","volume":"8","author":"JM Kraaijenhof","year":"2023","unstructured":"Kraaijenhof JM, Stroes ESG. Inflammatory effects of triglycerides: relevant or redundant? JACC Basic Transl Sci. 2023;8:476\u20138.","journal-title":"JACC Basic Transl Sci"},{"key":"10603_CR16","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American heart association. Circulation. 2023;148:1606\u201335.","journal-title":"Circulation"},{"issue":"5","key":"10603_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.bbalip.2011.10.003","volume":"1821","author":"S Subramanian","year":"2012","unstructured":"Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochimica et Biophysica Acta (BBA)-Mol Cell Biol Lipids. 2012;1821(5):819\u201325.","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol Cell Biol Lipids"},{"key":"10603_CR18","doi-asserted-by":"publisher","first-page":"e23","DOI":"10.1016\/S2666-7568(22)00247-1","volume":"4","author":"P Lopez-Jaramillo","year":"2023","unstructured":"Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, et al. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longevity. 2023;4:e23\u201333.","journal-title":"Lancet Healthy Longevity"},{"key":"10603_CR19","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/S0026-0495(96)90260-7","volume":"45","author":"DIW Phillips","year":"1996","unstructured":"Phillips DIW, Caddy S, Ilic V, et al. Intramuscular triglyceride and muscle insulin sensitivity: evidence for a relationship in nondiabetic subjects. Metabolism. 1996;45:947\u201350.","journal-title":"Metabolism"},{"key":"10603_CR20","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381:531\u201342.","journal-title":"N Engl J Med"},{"issue":"6","key":"10603_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum JL, Gaudet D, Freedman SD, et al. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N Engl J Med. 2019;381(6):531\u201342.","journal-title":"N Engl J Med"},{"key":"10603_CR22","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1089\/nat.2018.0736","volume":"28","author":"AD Springer","year":"2018","unstructured":"Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28:109\u201318.","journal-title":"Nucleic Acid Ther"},{"key":"10603_CR23","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa2400201","volume":"390","author":"ESG Stroes","year":"2024","unstructured":"Stroes ESG, Alexander VJ, Karwatowska-Prokopczuk E, et al. Olezarsen, acute pancreatitis, and familial chylomicronemia syndrome. N Engl J Med. 2024;390:1781\u201392.","journal-title":"N Engl J Med"},{"key":"10603_CR24","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for severe hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9:620\u201330.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10603_CR25","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1001\/jamacardio.2024.0959","volume":"9","author":"D Gaudet","year":"2024","unstructured":"Gaudet D, Pall D, Watts GF, et al. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: the SHASTA-2 randomized clinical trial. JAMA Cardiol. 2024;9(7):620\u201330.","journal-title":"JAMA Cardiol"},{"key":"10603_CR26","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1161\/CIRCULATIONAHA.122.059266","volume":"145","author":"BA Bergmark","year":"2022","unstructured":"Bergmark BA, Marston NA, Bramson CR, et al. Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol: TRANSLATE-TIMI 70. Circulation. 2022;145:1377\u201386.","journal-title":"Circulation"},{"key":"10603_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12944-021-01589-4","volume":"20","author":"MC Foss-Freitas","year":"2021","unstructured":"Foss-Freitas MC, Akinci B, Neidert A, et al. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study. Lipids Health Dis. 2021;20:174.","journal-title":"Lipids Health Dis"},{"key":"10603_CR28","doi-asserted-by":"publisher","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","volume":"41","author":"D Gaudet","year":"2020","unstructured":"Gaudet D, Karwatowska-Prokopczuk E, Baum SJ, et al. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. Eur Heart J. 2020;41:3936\u201345.","journal-title":"Eur Heart J"},{"key":"10603_CR29","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377:222\u201332.","journal-title":"N Engl J Med"},{"key":"10603_CR30","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42:8796\u2013807.","journal-title":"Nucleic Acids Res"},{"key":"10603_CR31","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","volume":"43","author":"KK Ray","year":"2022","unstructured":"Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. Eur Heart J. 2022;43:5047\u201357.","journal-title":"Eur Heart J"},{"key":"10603_CR32","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.atherosclerosis.2022.06.075","volume":"355","author":"A Hofherr","year":"2022","unstructured":"Hofherr A, Schumi J, Reki\u0107 D, et al. ETESIAN: A phase 2B study of the efficacy, safety and tolerability of AZD8233, a PCSK9-targeted antisense oligonucleotide, in patients with dyslipidemia. Atherosclerosis. 2022;355:28.","journal-title":"Atherosclerosis"},{"key":"10603_CR33","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.atherosclerosis.2022.03.029","volume":"349","author":"DA Rider","year":"2022","unstructured":"Rider DA, Eisermann M, L\u00f6ffler K, et al. Pre-clinical assessment of SLN360, a novel siRNA targeting LPA, developed to address elevated lipoprotein (a) in cardiovascular disease. Atherosclerosis. 2022;349:240\u20137.","journal-title":"Atherosclerosis"},{"key":"10603_CR34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","volume":"7","author":"F Duarte Lau","year":"2022","unstructured":"Duarte Lau F, Giugliano RP. Lipoprotein(a) and its significance in cardiovascular disease: a review. JAMA Cardiol. 2022;7:760\u20139.","journal-title":"JAMA Cardiol"},{"key":"10603_CR35","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O'Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. 2019;139:1483\u201392.","journal-title":"Circulation"},{"key":"10603_CR36","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1001\/jamacardio.2019.1041","volume":"4","author":"C Lamina","year":"2019","unstructured":"Lamina C, Kronenberg F. Estimation of the required lipoprotein(a)-lowering therapeutic effect size for reduction in coronary heart disease outcomes: a mendelian randomization analysis. JAMA Cardiol. 2019;4:575\u20139.","journal-title":"JAMA Cardiol"},{"key":"10603_CR37","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Rosenson RS, Gencer B, et al. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N Engl J Med. 2022;387:1855\u201364.","journal-title":"N Engl J Med"},{"key":"10603_CR38","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(10)60284-X","volume":"375","author":"FJ Raal","year":"2010","unstructured":"Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998\u20131006.","journal-title":"Lancet"},{"key":"10603_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00228-015-1992-y","volume":"72","author":"RZ Yu","year":"2016","unstructured":"Yu RZ, Gunawan R, Li Z, et al. No effect on QT intervals of mipomersen, a 2\u2019-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects. Eur J Clin Pharmacol. 2016;72:267\u201375.","journal-title":"Eur J Clin Pharmacol"},{"key":"10603_CR40","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen SE, Wolski K, Balog C, et al. Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA. 2022;327:1679\u201387.","journal-title":"JAMA"},{"key":"10603_CR41","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355.","journal-title":"N Engl J Med"},{"key":"10603_CR42","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"S Tsimikas","year":"2015","unstructured":"Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015;386:1472\u201383.","journal-title":"Lancet"},{"key":"10603_CR43","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Lipoprotein(a) Reduction in persons with cardiovascular disease. N Engl J Med. 2020;382:244\u201355.","journal-title":"N Engl J Med"},{"key":"10603_CR44","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet. 2016;388:2239\u201353.","journal-title":"Lancet"},{"key":"10603_CR45","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1001\/jama.2023.21835","volume":"330","author":"SE Nissen","year":"2023","unstructured":"Nissen SE, Linnebjerg H, Shen X, et al. Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial. JAMA. 2023;330:2075\u201383.","journal-title":"JAMA"},{"key":"10603_CR46","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1161\/CIRCRESAHA.122.321762","volume":"132","author":"M Burnier","year":"2023","unstructured":"Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res. 2023;132:1050\u201363.","journal-title":"Circ Res"},{"key":"10603_CR47","doi-asserted-by":"publisher","first-page":"42","DOI":"10.5049\/EBP.2008.6.1.42","volume":"6","author":"HE Yim","year":"2008","unstructured":"Yim HE, Yoo KH. Renin-angiotensin system - considerations for hypertension and kidney. Electrolyte Blood Press. 2008;6:42\u201350.","journal-title":"Electrolyte Blood Press"},{"key":"10603_CR48","doi-asserted-by":"publisher","first-page":"102344","DOI":"10.1016\/j.cpcardiol.2023.102344","volume":"49","author":"SA Sebastian","year":"2024","unstructured":"Sebastian SA, Padda I, Johal G. Cardiovascular-kidney-metabolic (CKM) syndrome: a state-of-the-art review. Curr Probl Cardiol. 2024;49:102344.","journal-title":"Curr Probl Cardiol"},{"key":"10603_CR49","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1161\/HYPERTENSIONAHA.122.18731","volume":"79","author":"EO Cruz-L\u00f3pez","year":"2022","unstructured":"Cruz-L\u00f3pez EO, Ye D, Wu C, et al. Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease. Hypertension. 2022;79:2115\u201326.","journal-title":"Hypertension"},{"key":"10603_CR50","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228\u201338.","journal-title":"N Engl J Med"},{"key":"10603_CR51","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2208391","volume":"389","author":"AS Desai","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023;389:228\u201338.","journal-title":"N Engl J Med"},{"key":"10603_CR52","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1001\/jama.2024.0728","volume":"331","author":"GL Bakris","year":"2024","unstructured":"Bakris GL, Saxena M, Gupta A, et al. RNA interference with zilebesiran for mild to moderate hypertension: the KARDIA-1 randomized clinical trial. JAMA. 2024;331:740\u20139.","journal-title":"JAMA"},{"key":"10603_CR53","doi-asserted-by":"publisher","first-page":"8796","DOI":"10.1093\/nar\/gku531","volume":"42","author":"TP Prakash","year":"2014","unstructured":"Prakash TP, Graham MJ, Yu J, et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 2014;42:8796\u2013807.","journal-title":"Nucleic Acids Res"},{"key":"10603_CR54","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"NJ Viney","year":"2016","unstructured":"Viney NJ, van Capelleveen JC, Geary RS, et al. Antisense oligonucleotides targeting apolipoprotein (a) in people with raised lipoprotein (a): two randomised, double-blind, placebo-controlled, dose-ranging trials. The Lancet. 2016;388:2239\u201353.","journal-title":"The Lancet"},{"key":"10603_CR55","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacbts.2021.04.004","volume":"6","author":"ES Morgan","year":"2021","unstructured":"Morgan ES, Tami Y, Hu K, et al. Antisense inhibition of angiotensinogen with IONIS-AGT-L(Rx): results of phase 1 and phase 2 studies. JACC Basic Transl Sci. 2021;6:485\u201396.","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"10603_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.3390\/cells8080859","volume":"8","author":"JF Landrier","year":"2019","unstructured":"Landrier JF, Derghal A, Mounien L. MicroRNAs in obesity and related metabolic disorders. Cells. 2019;8(8):859.","journal-title":"Cells"},{"key":"10603_CR57","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1055\/s-2007-973073","volume":"39","author":"C Wang","year":"2007","unstructured":"Wang C, Yang N, Wu S, Liu L, Sun X, Nie S. Difference of NPY and its receptor gene expressions between obesity and obesity-resistant rats in response to high-fat diet. Horm Metab Res. 2007;39:262\u20137.","journal-title":"Horm Metab Res"},{"key":"10603_CR58","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.molmet.2019.11.009","volume":"31","author":"S Wittrisch","year":"2020","unstructured":"Wittrisch S, Kl\u00f6ting N, M\u00f6rl K, Chakaroun R, Bl\u00fcher M, Beck-Sickinger AG. NPY1R-targeted peptide-mediated delivery of a dual PPAR\u03b1\/\u03b3 agonist to adipocytes enhances adipogenesis and prevents diabetes progression. Mol Metabolism. 2020;31:163\u201380.","journal-title":"Mol Metabolism"},{"issue":"8","key":"10603_CR59","doi-asserted-by":"publisher","first-page":"e2002176","DOI":"10.1371\/journal.pbio.2002176","volume":"15","author":"Z Bai","year":"2017","unstructured":"Bai Z, Chai X-r, Yoon MJ, et al. Dynamic transcriptome changes during adipose tissue energy expenditure reveal critical roles for long noncoding RNA regulators. PLoS Biol. 2017;15(8):e2002176.","journal-title":"PLoS Biol"},{"key":"10603_CR60","doi-asserted-by":"publisher","first-page":"101507","DOI":"10.1016\/j.molmet.2022.101507","volume":"61","author":"Y Ma","year":"2022","unstructured":"Ma Y, Murgia N, Liu Y, et al. Neuronal miR-29a protects from obesity in adult mice. Mol Metabolism. 2022;61:101507.","journal-title":"Mol Metabolism"},{"key":"10603_CR61","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1016\/j.bbalip.2016.02.010","volume":"1861","author":"NL Price","year":"2016","unstructured":"Price NL, Fern\u00e1ndez-Hernando C. miRNA regulation of white and brown adipose tissue differentiation and function. Biochimica et Biophysica Acta (BBA)-Mol Cell Biol Lipids. 2016;1861:2104\u201310.","journal-title":"Biochimica et Biophysica Acta (BBA)-Mol Cell Biol Lipids"},{"key":"10603_CR62","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1128\/MCB.00745-15","volume":"36","author":"NL Price","year":"2016","unstructured":"Price NL, Holtrup B, Kwei SL, et al. SREBP-1c\/MicroRNA 33b genomic loci control adipocyte differentiation. Mol Cell Biol. 2016;36:1180\u201393.","journal-title":"Mol Cell Biol"},{"key":"10603_CR63","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/ng.2606","volume":"45","author":"SI Berndt","year":"2013","unstructured":"Berndt SI, Gustafsson S, M\u00e4gi R, et al. Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture. Nat Genet. 2013;45:501\u201312.","journal-title":"Nat Genet"},{"key":"10603_CR64","doi-asserted-by":"publisher","first-page":"45","DOI":"10.7150\/jgen.3996","volume":"1","author":"T Kunej","year":"2013","unstructured":"Kunej T, Skok DJ, Zorc M, et al. Obesity gene atlas in mammals. J Genom. 2013;1:45.","journal-title":"J Genom"},{"key":"10603_CR65","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nrendo.2013.227","volume":"10","author":"RJ Loos","year":"2014","unstructured":"Loos RJ, Yeo GS. The bigger picture of FTO\u2014the first GWAS-identified obesity gene. Nat Rev Endocrinol. 2014;10:51\u201361.","journal-title":"Nat Rev Endocrinol"},{"key":"10603_CR66","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/S0960-9822(03)00250-1","volume":"13","author":"P Xu","year":"2003","unstructured":"Xu P, Vernooy SY, Guo M, Hay BA. The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol. 2003;13:790\u20135.","journal-title":"Curr Biol"},{"key":"10603_CR67","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s12013-014-9980-x","volume":"70","author":"L-l Xu","year":"2014","unstructured":"Xu L-l, Shi C-m, Xu G-f, et al. TNF-\u03b1, IL-6, and leptin increase the expression of miR-378, an adipogenesis-related microRNA in human adipocytes. Cell Biochem Biophys. 2014;70:771\u20136.","journal-title":"Cell Biochem Biophys"},{"key":"10603_CR68","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1096\/fj.14-260323","volume":"29","author":"JL Marques-Rocha","year":"2015","unstructured":"Marques-Rocha JL, Samblas M, Milagro FI, Bressan J, Mart\u00ednez JA, Marti A. Noncoding RNAs, cytokines, and inflammation-related diseases. FASEB J. 2015;29:3595\u2013611.","journal-title":"FASEB J"},{"key":"10603_CR69","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3390\/ijms24010139","volume":"24","author":"M Cabiati","year":"2022","unstructured":"Cabiati M, Randazzo E, Guiducci L, et al. Evaluation of exosomal coding and non-coding RNA signature in obese adolescents. Int J Mol Sci. 2022;24:139.","journal-title":"Int J Mol Sci"},{"key":"10603_CR70","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/pr.2014.202","volume":"77","author":"SC Ferrante","year":"2015","unstructured":"Ferrante SC, Nadler EP, Pillai DK, et al. Adipocyte-derived exosomal miRNAs: a novel mechanism for obesity-related disease. Pediatr Res. 2015;77:447\u201354.","journal-title":"Pediatr Res"},{"issue":"11","key":"10603_CR71","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.3390\/genes14112070","volume":"14","author":"JA Benavides-Aguilar","year":"2023","unstructured":"Benavides-Aguilar JA, Torres-Copado A, Isidoro-S\u00e1nchez J, et al. The regulatory role of MicroRNAs in obesity and obesity-derived ailments. Genes. 2023;14(11):2070.","journal-title":"Genes"},{"key":"10603_CR72","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1002\/oby.23365","volume":"30","author":"XY Huang","year":"2022","unstructured":"Huang XY, Chen JX, Ren Y, Fan LC, Xiang W, He XJ. Exosomal miR-122 promotes adipogenesis and aggravates obesity through the VDR\/SREBF1 axis. Obesity. 2022;30:666\u201379.","journal-title":"Obesity"},{"key":"10603_CR73","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s10142-021-00798-5","volume":"21","author":"S Sun","year":"2021","unstructured":"Sun S, Cao X, Castro LFC, Monroig \u00d3, Gao J. A network-based approach to identify protein kinases critical for regulating srebf1 in lipid deposition causing obesity. Funct Integr Genomics. 2021;21:557\u201370.","journal-title":"Funct Integr Genomics"},{"key":"10603_CR74","first-page":"815","volume":"21","author":"W Sun","year":"2020","unstructured":"Sun W, Sun X, Chu W, Yu S, Dong F, Xu G. CircRNA expression profiles in human visceral preadipocytes and adipocytes. Mol Med Rep. 2020;21:815\u201321.","journal-title":"Mol Med Rep"},{"key":"10603_CR75","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1073\/pnas.1222643110","volume":"110","author":"L Sun","year":"2013","unstructured":"Sun L, Goff LA, Trapnell C, et al. Long noncoding RNAs regulate adipogenesis. Proc Natl Acad Sci U S A. 2013;110:3387\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10603_CR76","doi-asserted-by":"publisher","first-page":"41440","DOI":"10.18632\/oncotarget.18269","volume":"8","author":"L Yu","year":"2017","unstructured":"Yu L, Tai L, Zhang L, Chu Y, Li Y, Zhou L. Comparative analyses of long non-coding RNA in lean and obese pig. Oncotarget. 2017;8:41440\u201350.","journal-title":"Oncotarget"},{"key":"10603_CR77","doi-asserted-by":"publisher","first-page":"e101261","DOI":"10.1371\/journal.pone.0101261","volume":"9","author":"Y Zhou","year":"2014","unstructured":"Zhou Y, Sun J, Li C, et al. Characterization of transcriptional complexity during adipose tissue development in bovines of different ages and sexes. PLoS ONE. 2014;9:e101261.","journal-title":"PLoS ONE"},{"key":"10603_CR78","doi-asserted-by":"publisher","first-page":"81994","DOI":"10.18632\/oncotarget.17813","volume":"8","author":"N Li","year":"2017","unstructured":"Li N, H\u00e9bert S, Song J, Kleinman CL, Richard S. Transcriptome profiling in preadipocytes identifies long noncoding RNAs as Sam68 targets. Oncotarget. 2017;8:81994\u20132005.","journal-title":"Oncotarget"},{"key":"10603_CR79","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/PRS.0000000000001582","volume":"136","author":"A Luan","year":"2015","unstructured":"Luan A, Paik KJ, Li J, et al. RNA sequencing for identification of differentially expressed noncoding transcripts during adipogenic differentiation of adipose-derived stromal cells. Plast Reconstr Surg. 2015;136:752\u201363.","journal-title":"Plast Reconstr Surg"},{"key":"10603_CR80","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker S, et al. ESC scientific document group. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC) developed with the special contribution of the heart failure association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"10603_CR81","doi-asserted-by":"publisher","unstructured":"Mohammadi A, Youssef I, Kobita I et al. Adherence to Guideline-Directed Medical Therapy in Heart Failure with Reduced Ejection Fraction: A Comparison Between Residents and Attending Physicians. 2025. PREPRINT (Version 1) available at Research Square. https:\/\/doi.org\/10.21203\/rs.3.rs-5649645\/v1.","DOI":"10.21203\/rs.3.rs-5649645\/v1"},{"key":"10603_CR82","doi-asserted-by":"publisher","unstructured":"Varjabedian L, Mohammadi A, Mohammadi A, Vaseghi Y. New Cardiovascular Medications: Surveying Adoption Trends Among Cardiologists. 2025. Available from: https:\/\/www.medrxiv.org\/content\/https:\/\/doi.org\/10.1101\/2025.01.14.25320511.abstract","DOI":"10.1101\/2025.01.14.25320511.abstract"},{"key":"10603_CR83","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ymthe.2018.11.018","volume":"27","author":"A Magadum","year":"2019","unstructured":"Magadum A, Kaur K, Zangi L. mRNA-based protein replacement therapy for the heart. Mol Ther. 2019;27:785\u201393.","journal-title":"Mol Ther"},{"key":"10603_CR84","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1126\/science.1174381","volume":"324","author":"A Bonauer","year":"2009","unstructured":"Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice. Science. 2009;324:1710\u20133.","journal-title":"Science"},{"key":"10603_CR85","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1161\/CIRCULATIONAHA.113.001904","volume":"128","author":"R Hinkel","year":"2013","unstructured":"Hinkel R, Penzkofer D, Z\u00fchlke S, et al. Inhibition of microRNA-92a protects against ischemia\/reperfusion injury in a large-animal model. Circulation. 2013;128:1066\u201375.","journal-title":"Circulation"},{"key":"10603_CR86","doi-asserted-by":"publisher","first-page":"e000946","DOI":"10.1161\/JAHA.114.000946","volume":"3","author":"N Bellera","year":"2014","unstructured":"Bellera N, Barba I, Rodriguez-Sinovas A, et al. Single intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse infarct remodeling. J Am Heart Assoc. 2014;3:e000946.","journal-title":"J Am Heart Assoc"},{"key":"10603_CR87","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1089\/nat.2020.0871","volume":"30","author":"WT Abplanalp","year":"2020","unstructured":"Abplanalp WT, Fischer A, John D, et al. Efficiency and target derepression of anti-miR-92a: results of a first in human study. Nucleic Acid Ther. 2020;30:335\u201345.","journal-title":"Nucleic Acid Ther"},{"key":"10603_CR88","doi-asserted-by":"publisher","first-page":"e24162","DOI":"10.1002\/clc.24162","volume":"47","author":"S Wang","year":"2024","unstructured":"Wang S, Lyu Y, Cheng S, et al. Appropriate time for ejection fraction reassessment after revascularization in patients with left ventricular dysfunction for risk stratification of sudden cardiac death. Clin Cardiol. 2024;47:e24162.","journal-title":"Clin Cardiol"},{"key":"10603_CR89","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/s41467-019-08852-4","volume":"10","author":"LM Gan","year":"2019","unstructured":"Gan LM, Lagerstr\u00f6m-Ferm\u00e9r M, Carlsson LG, et al. Intradermal delivery of modified mRNA encoding VEGF-A in patients with type 2 diabetes. Nat Commun. 2019;10:871.","journal-title":"Nat Commun"},{"key":"10603_CR90","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.omtm.2020.05.030","volume":"18","author":"V Anttila","year":"2020","unstructured":"Anttila V, Saraste A, Knuuti J, et al. Synthetic mRNA encoding VEGF-A in patients undergoing coronary artery bypass grafting: design of a phase 2a clinical trial. Mol Ther Methods Clin Dev. 2020;18:464\u201372.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10603_CR91","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41467-020-14349-2","volume":"11","author":"A Foinquinos","year":"2020","unstructured":"Foinquinos A, Batkai S, Genschel C, et al. Preclinical development of a miR-132 inhibitor for heart failure treatment. Nat Commun. 2020;11:633.","journal-title":"Nat Commun"},{"key":"10603_CR92","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1038\/ncomms2090","volume":"3","author":"A Ucar","year":"2012","unstructured":"Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012;3:1078.","journal-title":"Nat Commun"},{"key":"10603_CR93","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/eurheartj\/ehaa898","volume":"42","author":"J T\u00e4ubel","year":"2021","unstructured":"T\u00e4ubel J, Hauke W, Rump S, et al. Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. Eur Heart J. 2021;42:178\u201388.","journal-title":"Eur Heart J"},{"key":"10603_CR94","doi-asserted-by":"publisher","unstructured":"Kaushal N, Attarwala H, Iqbal MJ, Saini R, Van L, Liang M. Translational pharmacokinetic\/pharmacodynamic model for mRNA-0184, an investigational therapeutic for the treatment of heart failure. Clin Transl Sci. 2024;17(8). https:\/\/doi.org\/10.1111\/cts.13894.","DOI":"10.1111\/cts.13894"},{"key":"10603_CR95","doi-asserted-by":"publisher","first-page":"102053","DOI":"10.1016\/j.jbc.2022.102053","volume":"298","author":"SS Baksh","year":"2022","unstructured":"Baksh SS, Pratt RE, Gomez J, Dzau VJ, Hodgkinson CP. A novel Cbx1, PurB, and Sp3 complex mediates long-term silencing of tissue- and lineage-specific genes. J Biol Chem. 2022;298:102053.","journal-title":"J Biol Chem"},{"key":"10603_CR96","doi-asserted-by":"publisher","first-page":"e0223842","DOI":"10.1371\/journal.pone.0223842","volume":"14","author":"S Dal-Pra","year":"2019","unstructured":"Dal-Pra S, Hodgkinson CP, Dzau VJ. Induced cardiomyocyte maturation: cardiac transcription factors are necessary but not sufficient. PLoS ONE. 2019;14:e0223842.","journal-title":"PLoS ONE"},{"key":"10603_CR97","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1161\/CIRCRESAHA.116.308741","volume":"120","author":"S Dal-Pra","year":"2017","unstructured":"Dal-Pra S, Hodgkinson CP, Mirotsou M, Kirste I, Dzau VJ. Demethylation of H3K27 Is essential for the induction of direct cardiac reprogramming by miR combo. Circ Res. 2017;120:1403\u201313.","journal-title":"Circ Res"},{"key":"10603_CR98","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1161\/CIRCRESAHA.112.269035","volume":"110","author":"TM Jayawardena","year":"2012","unstructured":"Jayawardena TM, Egemnazarov B, Finch EA, et al. MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res. 2012;110:1465\u201373.","journal-title":"Circ Res"},{"key":"10603_CR99","doi-asserted-by":"publisher","first-page":"104694","DOI":"10.1016\/j.jbc.2023.104694","volume":"299","author":"H Sun","year":"2023","unstructured":"Sun H, Pratt RE, Dzau VJ, Hodgkinson CP. Neonatal and adult cardiac fibroblasts exhibit inherent differences in cardiac regenerative capacity. J Biol Chem. 2023;299:104694.","journal-title":"J Biol Chem"},{"key":"10603_CR100","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.yjmcc.2024.04.002","volume":"190","author":"H Sun","year":"2024","unstructured":"Sun H, Wang X, Pratt RE, Dzau VJ, Hodgkinson CP. C166 EVs potentiate miR cardiac reprogramming via miR-148a-3p. J Mol Cell Cardiol. 2024;190:48\u201361. https:\/\/doi.org\/10.1016\/j.yjmcc.2024.04.002.","journal-title":"J Mol Cell Cardiol."},{"key":"10603_CR101","first-page":"101310","volume":"31","author":"SS Baksh","year":"2022","unstructured":"Baksh SS, Hodgkinson CP. Conservation of miR combo based direct cardiac reprogramming. Biochem Biophys Rep. 2022;31:101310.","journal-title":"Biochem Biophys Rep"},{"issue":"Suppl_1","key":"10603_CR102","doi-asserted-by":"publisher","first-page":"A4142032","DOI":"10.1161\/circ.150.suppl_1.4142032","volume":"150","author":"A Mohammadi","year":"2024","unstructured":"Mohammadi A, Barney J, Jahan S, et al. Hospital discharge education for heart failure patients delivered by conversational agent technology improves patient experience and is preferred to a doctor or nurse. Circulation. 2024;150(Suppl_1):A4142032\u2013A4142032.","journal-title":"Circulation"},{"key":"10603_CR103","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","volume":"148","author":"CE Ndumele","year":"2023","unstructured":"Ndumele CE, Neeland IJ, Tuttle KR, et al. A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American heart association. Circulation. 2023;148:1636\u201364.","journal-title":"Circulation"},{"key":"10603_CR104","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/bs.pmbts.2023.12.013","volume":"203","author":"YV Nguyen Thi","year":"2024","unstructured":"Nguyen Thi YV, Ho TT, Caglayan S, Ramasamy TS, Chu DT. RNA therapeutics for treatment of diabetes. Prog Mol Biol Transl Sci. 2024;203:287\u2013300.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"5","key":"10603_CR105","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.3390\/ijms23052736","volume":"23","author":"H Zogg","year":"2022","unstructured":"Zogg H, Singh R, Ro S. Current advances in RNA therapeutics for human diseases. Int J Mol Sci. 2022;23(5):2736.","journal-title":"Int J Mol Sci"},{"key":"10603_CR106","doi-asserted-by":"publisher","first-page":"13267","DOI":"10.1038\/ncomms13267","volume":"7","author":"B Ekim \u00dcst\u00fcnel","year":"2016","unstructured":"Ekim \u00dcst\u00fcnel B, Friedrich K, Maida A, et al. Control of diabetic hyperglycaemia and insulin resistance through TSC22D4. Nat Commun. 2016;7:13267. https:\/\/doi.org\/10.1038\/ncomms13267.","journal-title":"Nat Commun"},{"key":"10603_CR107","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2337\/dc16-0126","volume":"39","author":"A Digenio","year":"2016","unstructured":"Digenio A, Dunbar RL, Alexander VJ, et al. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. Diabetes Care. 2016;39:1408\u201315.","journal-title":"Diabetes Care"},{"key":"10603_CR108","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/ATVBAHA.110.220723","volume":"31","author":"S Caron","year":"2011","unstructured":"Caron S, Verrijken A, Mertens I, et al. Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia. Arterioscler Thromb Vasc Biol. 2011;31:513\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10603_CR109","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S0140-6736(75)92375-2","volume":"1","author":"RH Unger","year":"1975","unstructured":"Unger RH, Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet. 1975;1:14\u20136.","journal-title":"Lancet"},{"key":"10603_CR110","doi-asserted-by":"publisher","first-page":"274","DOI":"10.2337\/diab.36.3.274","volume":"36","author":"AD Baron","year":"1987","unstructured":"Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes. 1987;36:274\u201383.","journal-title":"Diabetes"},{"key":"10603_CR111","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/jcph.396","volume":"55","author":"MG van Dongen","year":"2015","unstructured":"van Dongen MG, Geerts BF, Morgan ES, et al. First proof of pharmacology in humans of a novel glucagon receptor antisense drug. J Clin Pharmacol. 2015;55:298\u2013306.","journal-title":"J Clin Pharmacol"},{"key":"10603_CR112","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","volume":"50","author":"CF Bennett","year":"2010","unstructured":"Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10603_CR113","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2337\/dc18-1343","volume":"42","author":"ES Morgan","year":"2019","unstructured":"Morgan ES, Tai LJ, Pham NC, et al. Antisense inhibition of glucagon receptor by IONIS-GCGR(Rx) improves type 2 diabetes without increase in hepatic glycogen content in patients with type 2 diabetes on stable metformin therapy. Diabetes Care. 2019;42:585\u201393.","journal-title":"Diabetes Care"},{"key":"10603_CR114","doi-asserted-by":"publisher","first-page":"1250073","DOI":"10.3389\/fcvm.2023.1250073","volume":"10","author":"TC Palmer","year":"2023","unstructured":"Palmer TC, Hunter RW. Using RNA-based therapies to target the kidney in cardiovascular disease. Front Cardiovasc Med. 2023;10:1250073.","journal-title":"Front Cardiovasc Med"},{"issue":"3","key":"10603_CR115","doi-asserted-by":"publisher","first-page":"340","DOI":"10.3390\/medicina58030340","volume":"58","author":"SY Yoon","year":"2022","unstructured":"Yoon SY, Kim JS, Jeong KH, Kim SK. Acute kidney injury: biomarker-guided diagnosis and management. Medicina. 2022;58(3):340.","journal-title":"Medicina"},{"key":"10603_CR116","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1161\/CIRCULATIONAHA.120.053029","volume":"144","author":"M Thielmann","year":"2021","unstructured":"Thielmann M, Corteville D, Szabo G, et al. Teprasiran, a small interfering RNA, for the prevention of acute kidney injury in high-risk patients undergoing cardiac surgery: a randomized clinical study. Circulation. 2021;144:1133\u201344.","journal-title":"Circulation"},{"key":"10603_CR117","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1007\/s00134-022-06859-y","volume":"48","author":"P Pickkers","year":"2022","unstructured":"Pickkers P, Murray PT, Ostermann M. New drugs for acute kidney injury. Intensive Care Med. 2022;48:1796\u20138.","journal-title":"Intensive Care Med"},{"key":"10603_CR118","doi-asserted-by":"publisher","first-page":"147916412110588","DOI":"10.1177\/14791641211058856","volume":"18","author":"S Thipsawat","year":"2021","unstructured":"Thipsawat S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature. Diab Vasc Dis Res. 2021;18:14791641211058856.","journal-title":"Diab Vasc Dis Res"},{"key":"10603_CR119","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.semnephrol.2010.03.007","volume":"30","author":"GH Tesch","year":"2010","unstructured":"Tesch GH. Macrophages and diabetic nephropathy. Semin Nephrol. 2010;30:290\u2013301.","journal-title":"Semin Nephrol"},{"key":"10603_CR120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/ndt\/gfx170.MP393","volume":"32","author":"J Menne","year":"2017","unstructured":"Menne J, Eulberg D, Beyer D, et al. C-C motif-ligand 2 inhibition with emapticap pegol (NOX-E36) in type 2 diabetic patients with albuminuria. Nephrol Dial Transplant. 2017;32:307\u201315.","journal-title":"Nephrol Dial Transplant"},{"key":"10603_CR121","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1056\/NEJMra1301564","volume":"369","author":"P Cochat","year":"2013","unstructured":"Cochat P, Rumsby G. Primary hyperoxaluria. N Engl J Med. 2013;369:649\u201358.","journal-title":"N Engl J Med"},{"key":"10603_CR122","doi-asserted-by":"publisher","first-page":"1052625","DOI":"10.3389\/fped.2022.1052625","volume":"10","author":"X Gang","year":"2022","unstructured":"Gang X, Liu F, Mao J. Lumasiran for primary hyperoxaluria type 1: what we have learned? Front Pediatr. 2022;10:1052625.","journal-title":"Front Pediatr"},{"key":"10603_CR123","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","volume":"384","author":"SF Garrelfs","year":"2021","unstructured":"Garrelfs SF, Frishberg Y, Hulton SA, et al. Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med. 2021;384:1216\u201326.","journal-title":"N Engl J Med"},{"key":"10603_CR124","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/j.ekir.2024.04.048","volume":"9","author":"JM Saland","year":"2024","unstructured":"Saland JM, Lieske JC, Groothoff JW, et al. Efficacy and safety of lumasiran in patients with primary hyperoxaluria type 1: results from a phase III clinical trial. Kidney Int Rep. 2024;9:2037\u201346.","journal-title":"Kidney Int Rep"},{"key":"10603_CR125","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s00467-022-05684-1","volume":"38","author":"W Hayes","year":"2023","unstructured":"Hayes W, Sas DJ, Magen D, et al. Efficacy and safety of lumasiran for infants and young children with primary hyperoxaluria type 1: 12-month analysis of the phase 3 ILLUMINATE-B trial. Pediatr Nephrol. 2023;38:1075\u201386.","journal-title":"Pediatr Nephrol"},{"key":"10603_CR126","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/j.ajkd.2022.05.012","volume":"81","author":"M Michael","year":"2023","unstructured":"Michael M, Groothoff JW, Shasha-Lavsky H, et al. Lumasiran for advanced primary hyperoxaluria type 1: phase 3 ILLUMINATE-C trial. Am J Kidney Dis. 2023;81:145-55.e1.","journal-title":"Am J Kidney Dis"},{"key":"10603_CR127","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-023-01987-1","volume":"84","author":"C Kang","year":"2024","unstructured":"Kang C. Lumasiran: a review in primary hyperoxaluria type 1. Drugs. 2024;84:219\u201326.","journal-title":"Drugs"},{"key":"10603_CR128","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","volume":"83","author":"YY Syed","year":"2023","unstructured":"Syed YY. Nedosiran: first approval. Drugs. 2023;83:1729\u201333.","journal-title":"Drugs"},{"key":"10603_CR129","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","volume":"103","author":"MA Baum","year":"2023","unstructured":"Baum MA, Langman C, Cochat P, et al. PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2. Kidney Int. 2023;103:207\u201317.","journal-title":"Kidney Int"},{"issue":"19","key":"10603_CR130","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1001\/jama.2018.15870","volume":"320","author":"E Meijer","year":"2018","unstructured":"Meijer E, Visser FW, van Aerts RMM, et al. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial. JAMA. 2018;320(19):2010\u20139. https:\/\/doi.org\/10.1001\/jama.2018.15870.","journal-title":"JAMA."},{"key":"10603_CR131","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ekir.2019.12.007","volume":"5","author":"IY Kuo","year":"2020","unstructured":"Kuo IY, Chapman AB. Polycystins, ADPKD, and cardiovascular disease. Kidney Int Rep. 2020;5:396\u2013406.","journal-title":"Kidney Int Rep"},{"key":"10603_CR132","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1007\/s40265-022-01745-9","volume":"82","author":"T Bais","year":"2022","unstructured":"Bais T, Gansevoort RT, Meijer E. Drugs in clinical development to treat autosomal dominant polycystic kidney disease. Drugs. 2022;82:1095\u2013115.","journal-title":"Drugs"},{"key":"10603_CR133","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham MJ, Lee RG, Brandt TA, et al. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N Engl J Med. 2017;377:222\u201332.","journal-title":"N Engl J Med"},{"key":"10603_CR134","doi-asserted-by":"publisher","first-page":"e1484","DOI":"10.1002\/ctm2.1484","volume":"13","author":"GF Watts","year":"2023","unstructured":"Watts GF, Chan DC. RNA interference therapy for targeting ANGPTL3 and atherogenic lipoproteins: findings and implications of a recent phase I study. Clin Transl Med. 2023;13:e1484.","journal-title":"Clin Transl Med"},{"key":"10603_CR135","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1038\/s41591-023-02494-2","volume":"29","author":"GF Watts","year":"2023","unstructured":"Watts GF, Schwabe C, Scott R, et al. RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts. Nat Med. 2023;29:2216\u201323.","journal-title":"Nat Med"},{"key":"10603_CR136","unstructured":"Study of ARO-ANG3 in adults with mixed dyslipidemia (ARCHES-2). at https:\/\/clinicaltrials.gov\/study\/NCT04832971. Accessed 7 Dec 2024"},{"issue":"1","key":"10603_CR137","doi-asserted-by":"publisher","first-page":"87","DOI":"10.33590\/emjcardiol\/10303462","volume":"11","author":"CE Kosmas","year":"2023","unstructured":"Kosmas CE, Papakonstantinou EJ, Carre\u00f1o J, Uceta RE, Guzman E, Sourlas A. PCSK9 targeting in the management of hypercholesterolaemia. EMJ Cardiol. 2023;11(1):87\u201397.","journal-title":"EMJ Cardiol"},{"key":"10603_CR138","doi-asserted-by":"publisher","first-page":"1006307","DOI":"10.3389\/fgene.2022.1006307","volume":"13","author":"W Yin","year":"2022","unstructured":"Yin W, Zhang Z, Xiao Z, Li X, Luo S, Zhou Z. Circular RNAs in diabetes and its complications: current knowledge and future prospects. Front Genet. 2022;13:1006307.","journal-title":"Front Genet"},{"key":"10603_CR139","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1111\/jcmm.15295","volume":"24","author":"J Jin","year":"2020","unstructured":"Jin J, Sun H, Shi C, et al. Circular RNA in renal diseases. J Cell Mol Med. 2020;24:6523\u201333.","journal-title":"J Cell Mol Med"},{"key":"10603_CR140","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1172\/JCI75852","volume":"125","author":"IG Gomez","year":"2015","unstructured":"Gomez IG, MacKenna DA, Johnson BG, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest. 2015;125:141\u201356.","journal-title":"J Clin Invest"},{"issue":"4","key":"10603_CR141","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/cells11040594","volume":"11","author":"D Rubel","year":"2022","unstructured":"Rubel D, Boulanger J, Craciun F, et al. Anti-microRNA-21 therapy on top of ACE inhibition delays renal failure in Alport syndrome mouse models. Cells. 2022;11(4):594.","journal-title":"Cells"},{"key":"10603_CR142","doi-asserted-by":"publisher","first-page":"628137","DOI":"10.3389\/fbioe.2021.628137","volume":"9","author":"TR Damase","year":"2021","unstructured":"Damase TR, Sukhovershin R, Boada C, Taraballi F, Pettigrew RI, Cooke JP. The limitless future of RNA therapeutics. Front Bioeng Biotechnol. 2021;9:628137.","journal-title":"Front Bioeng Biotechnol"},{"key":"10603_CR143","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12967-021-02751-3","volume":"19","author":"Y Song","year":"2021","unstructured":"Song Y, Choi J-E, Kwon Y-J, et al. Identification of susceptibility loci for cardiovascular disease in adults with hypertension, diabetes, and dyslipidemia. J Transl Med. 2021;19:85.","journal-title":"J Transl Med"},{"key":"10603_CR144","doi-asserted-by":"publisher","first-page":"e24380","DOI":"10.1002\/jcla.24380","volume":"36","author":"G Mahjoob","year":"2022","unstructured":"Mahjoob G, Ahmadi Y, Fatima Rajani H, Khanbabaei N, Abolhasani S. Circulating microRNAs as predictive biomarkers of coronary artery diseases in type 2 diabetes patients. J Clin Lab Anal. 2022;36:e24380.","journal-title":"J Clin Lab Anal"},{"key":"10603_CR145","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/cvr\/cvx211","volume":"114","author":"JPG Sluijter","year":"2017","unstructured":"Sluijter JPG, Davidson SM, Boulanger CM, et al. Extracellular vesicles in diagnostics and therapy of the ischaemic heart: position paper from the working group on cellular biology of the heart of the European society of cardiology. Cardiovasc Res. 2017;114:19\u201334.","journal-title":"Cardiovasc Res"},{"key":"10603_CR146","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jconrel.2024.04.018","volume":"369","author":"MCI Labonia","year":"2024","unstructured":"Labonia MCI, Estap\u00e9 Senti M, van der Kraak PH, et al. Cardiac delivery of modified mRNA using lipid nanoparticles: cellular targets and biodistribution after intramyocardial administration. J Control Release. 2024;369:734\u201345.","journal-title":"J Control Release"},{"key":"10603_CR147","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K, White S, Borodovsky A, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376:41\u201351.","journal-title":"N Engl J Med"},{"key":"10603_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-50600-8","volume":"14","author":"W DeGroat","year":"2024","unstructured":"DeGroat W, Abdelhalim H, Patel K, Mendhe D, Zeeshan S, Ahmed Z. Discovering biomarkers associated and predicting cardiovascular disease with high accuracy using a novel nexus of machine learning techniques for precision medicine. Sci Rep. 2024;14:1.","journal-title":"Sci Rep"},{"key":"10603_CR149","doi-asserted-by":"publisher","first-page":"e010007","DOI":"10.1161\/JAHA.118.010007","volume":"7","author":"DT Ko","year":"2018","unstructured":"Ko DT, Khan AM, Kotrri G, et al. Eligibility, clinical outcomes, and budget impact of PCSK9 inhibitor adoption: the CANHEART PCSK9 study. J Am Heart Assoc. 2018;7:e010007.","journal-title":"J Am Heart Assoc"},{"key":"10603_CR150","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.3390\/ijms25063383","volume":"25","author":"Y Liu","year":"2024","unstructured":"Liu Y, Dong J-H, Shen X-Y, et al. Qualitative and quantitative analytical techniques of nucleic acid modification based on mass spectrometry for biomarker discovery. Int J Mol Sci. 2024;25:3383.","journal-title":"Int J Mol Sci"},{"key":"10603_CR151","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","volume":"40","author":"KM Brown","year":"2022","unstructured":"Brown KM, Nair JK, Janas MM, et al. Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates. Nat Biotechnol. 2022;40:1500\u20138.","journal-title":"Nat Biotechnol"},{"key":"10603_CR152","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin U, Karik\u00f3 K, T\u00fcreci \u00d6. mRNA-based therapeutics \u2014 developing a new class of drugs. Nat Rev Drug Discovery. 2014;13:759\u201380.","journal-title":"Nat Rev Drug Discovery"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-025-10603-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-025-10603-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T15:06:12Z","timestamp":1757948772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-025-10603-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":152,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10603"],"URL":"https:\/\/doi.org\/10.1007\/s12265-025-10603-4","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]},"assertion":[{"value":"22 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this study is a review article that synthesizes and analyzes previously published data, it does not involve human participants or animals. Therefore, ethical approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This article is a review of previously published data and does not involve human participants or original research requiring consent to participate. Therefore, consent to participate is not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"This article does not include individual data or identifiable information from participants. Consent to publish is not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no disclosure.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"In preparing this review article, we utilized large language models (LLMs) to assist with grammatical revisions and diction improvements, enhancing clarity and readability.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Language Assistance Disclosure"}},{"value":"The authors declare that they have no conflict of interest.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}